And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40499143.
- Also identified by DOI 10.1158/1078-0432.CCR-25-1089 and PMC identifier 12353176.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drug development targeting CD137 has been historically fraught because of concerns over safety and efficacy. A deeper understanding of CD137 function and insights into why earlier CD137 agonists failed have set the stage for a new generation of promising CD137 therapeutics. See related article by de Bono et al., p. 3388.
Medical subject headings
- Tumor Necrosis Factor Receptor Superfamily, Member 9
- Neoplasms
- Immunotherapy